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Chronic hepatitis C virus (HCV) infection is a well-recognized risk factor for hepatocellular 
carcinoma (HCC). As a co-risk factor, the role of tobacco use in HCV-driven carcinogenesis and 
relevant underlying mechanisms remain largely unclear. The latest discoveries about HCV 
replication have shown that HCV RNA hijacks cellular miRNA-122 by forming an Ago2-HCV-
miR-122 complex that stabilizes the HCV genome and enhances HCV replication. Our previous 
work has demonstrated that aqueous tobacco smoke extract (TSE) is a potent activator 
of HIV replication via TSE-mediated viral protection from oxidative stress and activation of a set 
of genes that can promote viral replication. Since HCV is, like HIV, an enveloped virus that 
should be equally susceptible to lipid peroxidation, and since one of the TSE-upregulated genes, 
the DDX3 helicase, is known to facilitate HCV replication, we hypothesize that (1) tobacco use 
can similarly enhance HCV viability and replication, and promote HCC progression by up-
regulation of DDX3, and (2) by competing for binding with miR-122 as a competing endogenous 
RNA (ceRNA), HCV replication can liberate miR-122’s direct target, oncogenic gene cyclin 
G1 (CCNG1); furthermore, simultaneous tobacco use can synergistically enhance this competing 
effect via HCV upregulation. Our hypotheses may lay a foundation for better understanding of 
carcinogenesis in HCV-driven HCC and the potential role of tobacco as a cofactor. Disrupting 
the HCV ceRNA effect may provide a new strategy for designing anti HCV/HCC drugs. 
 






Chronic hepatitis C virus (HCV) infection is a well recognized risk factor for hepatocellular 
carcinoma (HCC) [1]. Tobacco use increases the risk of HCC in those with HCV 
infection [2], [3]. However, the molecular mechanisms that underlie the interaction between 
tobacco use and HCV infection and the consequent carcinogenesis remain largely unclear. 
Elucidation of the underlying mechanisms may not only reveal the role of tobacco use in HCV-
driven HCC from a public health perspective, but also provide new targets for developing anti-
HCV/HCC drugs. 
 
A body of evidence suggests that liver specific microRNA miR-122 promotes HCV replication 
by binding with 5′ terminal nucleotides of the HCV genome [4], with the Ago2-miR-122 
complex masking and stabilizing HCV RNA against 5′ exonuclease degradation [5], [6], [7]. The 
interaction between miR-122 and HCV RNA implies that HCV replication can sequester miR-
122, as suggested by Lemon and coworkers [7]. A novel mechanism for regulation of gene 
expression has been suggested recently, known as competing endogenous mRNA (ceRNA) [8]. 
Mechanistically, two mRNAs sharing common microRNAs will compete for binding to those 
microRNAs. Thus, the transcription of one gene will compete for binding to the shared 
microRNA and liberate the RNA of the other gene, increasing its expression. This mechanism 
for the regulation of gene expression has been proven in several cases [9], [10]. 
 
Human DDX3, a DEAD (Asp-Glu-Ala-Asp)-box RNA helicase, is involved in HCV translation, 
replication and hepatocarcinogenesis [11], [12]. Up-regulation of DDX3 promotes the expression 
of Snail, an inducer of the epithelial to mesenchymal transition (EMT), thereby contributing to 
the progression of some cancers [12], such as in the transformation of breast epithelial cells [13]. 
 
Our previous study [14] revealed that tobacco smoke extract (TSE) can enhance HIV viability, 





Figure 1. Hypothesis chart. ( )Known flow ( ) Hypothesized flow EMT: epithelial-
mesenchymal transition. 
 
Based on this background and the results of our previous study, we hypothesize that tobacco use 
can promote HCV-driven hepatocarcinogenesis. Mechanistically, tobacco use can enhance HCV 
viability and replication, and promote HCC progression, either via its anti-oxidant potential or by 
up-regulating DDX3, and HCV replication can act as ceRNA to liberate miR-122’s direct 
target, oncogenic gene CCNG1; simultaneous tobacco use can synergistically enhance this 
ceRNA effect via HCV upregulation (Fig. 1). 
 
Evaluation of the hypotheses 
 
The direct effect of tobacco use on HCV replication 
 
The current knowledge that tobacco use has a synergistic effect on HCV-driven HCC is mainly 
from epidemiological studies [1], [2], [15], [16]. The underlying molecular mechanisms for the 
direct interactions between tobacco use and HCV infection have not been definitively 
established. So far, few studies have been performed at the cellular and genetic level to elucidate 
their interactions in hepatocarcinogenesis. In our previous study [14], we showed that TSE has 
anti-oxidant potential to protect HIV and HIV-infected cells from peroxidative stress; TSE can 
also induce the up-regulation of DDX3 in human T cells. Since TSE used in the experiment has a 
nicotine concentration within the range of that in the plasma of smokers, we therefore assume the 
effect of TSE in our in vitro experiments is equivalent to that in vivo. Because HCV, like HIV, is 
an enveloped virus susceptible to lipid peroxidation, and thus could benefit from the protective 
effect of TSE, and since DDX3 is important for HCV replication, we hypothesize that tobacco 
smoke has similar positive effects on HCV replication. Given that DDX3 is required for HCV 
replication [11], [17], [18], our hypothesis will bridge the gap between the role of tobacco use 
and HCV replication, via the role of DDX3. 
 
Genes and transduction signaling pathways involved in the effect of tobacco use on HCV-driven 
carcinogenesis 
 
Epidemiological studies have shown tobacco use is a co-risk factor for HCV-driven HCC, but 
the molecular link between tobacco use and HCC has not been fully defined. We have identified 
a direct effect of TSE on the up-regulation of DDX3 [14]. Significantly, DDX3 has ability to 
promote cancer progression by up-regulating the expression of Snail, a transcription factor 
known as an inducer of EMT [12]. Our hypothesis of the direct effect of TSE on the expression 
of DDX3 and the consequent activation of EMT signaling may provide a molecular link between 
tobacco use and hepatocarcinogenesis. The role of DDX3 in HCV replication has been well 
established by several studies [11], [18], [19]. Again, our published study shows that TSE has the 
ability to stimulate the up-regulation of DDX3 in T cells. Since HCV infection and tobacco use 
are co-risk factors in the progression of HCC, there is a high probability that tobacco use could 
enhance HCV replication through activation of DDX3. Establishment of a probable role of 
DDX3 in tobacco-induced progression of HCV infection may not only reveal the mechanism of 
hazards of smoking, but also implicate DDX3 as a therapeutic drug target for HCV infection. 
 
ceRNA theory describes the “sequestering” effect of HCV on liver specific miR-122 and its 
consequences 
 
It is quite clear that liver specific miR-122 has a unique ability to bind to HCV genomic RNA to 
stimulate HCV replication [6], [7], [20]. In turn, HCV replication will “sponge up” miR-122, as 
Lemon and coworkers have proposed, via a “hijacking” or “sequestering” effect [7]. We invoke a 
recently discovered gene expression regulation mechanism, ceRNA theory [8], [10], to describe 
the proposed “hijacking” effect and extend to its consequences. In this case, HCV RNA and 
CCNG1, the direct target gene of miR-122, will compete for binding of limited amounts of 
cellular miR-122. The more HCV RNA, the more miR-122 will be sequestered, and the more 
CCNG1 gene expression will be rescued. miR-122 has liver-specific functions in the regulation 
of lipid metabolism, inflammation and regulation of its direct target gene, CCNG1 [21]. With 
“hijacking”, HCV replication and the enhancing effect of tobacco use on HCV will greatly 
liberate the direct target of miR-122 and result in the rescuing of CCNG1, an oncogenic 
gene that has been identified as a major player in carcinogenesis in liver [22] and other 
cancers [23]. The main downstream signaling of CCNG1 is the process of EMT [22], which can 
converge with the effect of DDX3 on Snail signaling as stated above. Based on these factors, we 
hypothesize a mechanism whereby the HCV ceRNA effect is expected to promote 
hepatocarcinogenesis, and tobacco use will enhance the effect. Assessment of this HCV ceRNA 
hypothesis may advance our understanding of the interactions between HCV infection and host 





Our hypotheses focus on direct interactions between tobacco smoke and virus activation, and 
invoke a HCV “ceRNA theory” as a molecular mechanism for HCV-driven carcinogenesis. 
 
Given the dual functions of miR-122 in HCV infection [20], [24], [25] and HCC 
carcinogenesis [21], several therapies based on miR-122 have been suggested [21], [26], [27]. 
On one hand, being an enhancer of HCV replication, miR-122 is a target for silencing in the 
treatment of HCV [26], [28]. However, deletion of miR-122 in mouse liver results in 
hepatosteatosis, hepatitis, and the development of tumors resembling HCC [21]. On the other 
hand, miR-122 inhibits tumorigenesis by directly targeting oncogenic CCNG1, as well as Wnt/β-
catenin and N-myc downstream-regulated gene 3 (NDRG3) pathways [25]. In the EMT of HCC, 
the down-regulation of miR-122 [29] gives rise to up-regulation of CCNG1 and consequent Snail 
and PI3 K/Akt activation [22]. In patients with hepatitis B, loss of miR-122 enhances HBV 
replication via CCNG1-modulated p53 activity [30]. As a tumor-suppressor, delivery of miR-122 
to a MYC-driven mouse model of HCC has shown a strong inhibitory effect on 
tumorigenesis [21]. Nevertheless, a potential side effect of miR-122 mimicry therapy for HCC 
cannot be excluded due to its enhancing effect on HCV replication. Because of the dual roles of 
miR-122 in both HCV infection and hepatocarcinogenesis, a balanced miR-122 based therapy 
for HCV/HCC is required [27]. 
 
Since up-regulation of DDX3 induced by TSE and up-regulation of CCNG1 induced by the HCV 
ceRNA effect both have a role in promoting EMT through Snail and PI3 K/Akt 
signaling [12], [22], elucidation of the HCV ceRNA theory will lay a foundation for better 
understanding of carcinogenesis in HCV-driven HCC and the potential role of tobacco as a 
cofactor. Disrupting the HCV ceRNA effect, not merely silencing or over-expressing miR-122, 
will provide a new strategy for designing anti HCV/HCC drugs. Our hypotheses may also have 
an impact on public awareness about the hazards of tobacco use, especially for patients with viral 
hepatitis. 
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